NCT06960564

Brief Summary

In this study, the effect of intra-articular HA injection therapy on pre- and post-treatment TNF-alpha and IL-1beta levels and methylation changes in blood and synovial fluid in patients with knee osteoarthritis will be determined and compared with the placebo group. In addition, the effects of HA injection on pain, functional status and quality of life will be evaluated and these effects will be related to changes in TNF-alpha and IL-1-beta.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P25-P50 for not_applicable knee-osteoarthritis

Timeline
Completed

Started May 2025

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 28, 2025

Completed
9 days until next milestone

First Posted

Study publicly available on registry

May 7, 2025

Completed
5 days until next milestone

Study Start

First participant enrolled

May 12, 2025

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 30, 2026

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 29, 2026

Completed
Last Updated

January 9, 2026

Status Verified

June 1, 2025

Enrollment Period

9 months

First QC Date

April 28, 2025

Last Update Submit

January 8, 2026

Conditions

Outcome Measures

Primary Outcomes (4)

  • Blood and synovial fluid TNF-alpha levels

    Assessments will be made before and 1 week after treatment

  • Blood and synovial fluid IL-1beta levels

    Assessments will be made before and 1 week after treatment

  • Blood and synovial fluid TNF-alpha methylation changes

    Assessments will be made before and 1 week after treatment

  • Blood and synovial fluid IL-1beta methylation changes

    Assessments will be made before and 1 week after treatment

Secondary Outcomes (3)

  • Visual Analogue Scale (VAS)-pain (activity, rest, night)

    Evaluations will be performed before and 1 month, 3 months and 6 months after treatment

  • The Western Ontario and McMaster Universities Arthritis Index (WOMAC)- (pain, stiffness, physical function, total score)

    Evaluations will be performed before and 1 month, 3 months and 6 months after treatment

  • Lequesne Index (pain or discomfort, walking distance, GYA)

    Evaluations will be performed before and 1 month, 3 months and 6 months after treatment

Study Arms (2)

Intra-articular hyaluronic acid injection group

ACTIVE COMPARATOR
Device: Hyaluronic Acid injections

Intra-articular saline injection group

PLACEBO COMPARATOR
Other: Saline -- placebo comparator

Interventions

Intra-articular hyaluronic acid will be administered to 30 selected patients. Blood and synovial fluid samples will be collected before HA injection and 1 week after 3 sessions of HA injection with one week interval. Home exercise programme will be given.

Intra-articular hyaluronic acid injection group

Intra-articular saline (SF) will be administered to 20 selected patients. Blood and synovial fluid samples will be collected before and 1 week after 3 session of salin injection with one week interval. Home exercise programme will be given.

Intra-articular saline injection group

Eligibility Criteria

Age45 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Diagnosis of knee osteoarthritis according to ACR (American College of Rheumatology) criteria
  • Knee pain for more than 3 months
  • Presence of knee pain resistant to conservative treatment for at least 3 months
  • To be between the ages of 45-75
  • Kellgren-Lawrence stage 2-3 gonarthrosis detected in the available knee direct radiographs of the patients

You may not qualify if:

  • Patients with KL stage 1 and 4 OA
  • Systematic diseases (severe cardiovascular disease, severe renal failure, severe hepatic failure, uncontrolled diabetes, cancer, immunosuppression, haematological diseases, systemic bone diseases)
  • Bleeding tendency (acquired or inherited) \[lNR\>2 in a patient on Coumadin\],
  • Infection (systemic or local)
  • Secondary knee osteoarthritis (inflammatory joint disease, post-traumatic, post-infectious, etc.)
  • Major knee trauma within the last 1 year
  • BMI \>40
  • History of total knee or hip arthroplasty within 1 year
  • Pregnancy
  • History of intra-articular injection within the last 6 months
  • Patients with Hb less than 11 g/dl and Plt less than 150.000
  • Presence of allergy to hyaluronic acid products

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Istanbul University, Istanbul Faculty of Medicine

Istanbul, Turkey (Türkiye)

RECRUITING

MeSH Terms

Conditions

Osteoarthritis, Knee

Condition Hierarchy (Ancestors)

OsteoarthritisArthritisJoint DiseasesMusculoskeletal DiseasesRheumatic Diseases

Central Study Contacts

Dicle Rotinda Özdaş Sevgin

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

April 28, 2025

First Posted

May 7, 2025

Study Start

May 12, 2025

Primary Completion

January 30, 2026

Study Completion

March 29, 2026

Last Updated

January 9, 2026

Record last verified: 2025-06

Locations